Abstracts tagged "Eye Disorders"

Abstract Number: 1853 • ACR Convergence 2024
Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome
Leah Huey¹, Emily Vance¹, Kofi Asare-Konadu² and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Blau syndrome, a pediatric rheumatological disease characterized by uveitis, arthritis, and dermatitis, is caused by a single point mutation in the gene NOD2. Nod2…
Abstract Number: 1961 • ACR Convergence 2024
Salivary and Lacrimal Glands Ultrasonography in Systemic Lupus Erythematosus Patients
Mohammadrafi Damirchi¹, Nafiseh Abdolahi², Fatemeh Hosseini³, Mohadeseh Mohammadi³, Mina Khosravi⁴, Zahra Niakan¹ and Siavash Abbasi³, ¹Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, ²Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Melbourne, Australia, ³Department of Radiology, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, ⁴Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition that can manifest in various ways, such as oral and eye-related symptoms, which may overlap…
Abstract Number: 2033 • ACR Convergence 2024
Scleritis and the Rheumatologist. Does the Type of Scleritis Help to Distinguish an Infectious Cause from an Immune Cause? Among the Immune Causes, Does It Help Differentiate Between Systemic Causes and Those Limited to the Eye?
Hanna Caroline Antunes Dos Santos¹, Zoraida Sachetto¹, Rodrigo da rocha jorge¹, Gabriela Vilaça Gutierrez¹, Renata Froes Ramos de lima¹, Ananda Ribeiro Fretes¹, Maria Fernanda zacarin¹, Roberto dos reis¹ and Alisson Pugliesi², ¹Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil, ²Unicamp, Campinas, Brazil
Background/Purpose: Ophthalmologists increasingly call rheumatologists for the evaluation and treatment of scleritis. Although they can be of immune etiology (systemic or restricted to the eye),…
Abstract Number: 2055 • ACR Convergence 2024
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
Laura Kopplin¹ and Karen Armbrust², ¹Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, ²Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN
Background/Purpose: Scleritis is a rare, potentially vision threatening ocular inflammatory disease. 30-40% of scleritis is associated with systemic autoimmune diseases with reports of worse visual…
Abstract Number: 0296 • ACR Convergence 2024
Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Laura Mas Sánchez¹, JOSE ELOY OLLER RODRIGUEZ², Elena Grau García³, Carmen Riesco Barcena⁴, SAMUEL LEAL⁵, Marta de la Rubia navarro⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Alba Torrat noves⁹, Daniel Ramos Castro¹⁰, Iago Alcantara Alvarez¹¹, Belén Villanueva Mañés¹¹, Miguel Simeo Vinaixa¹², Andrés Pérez Hurtado¹³ and Jose A Román-Ivorra¹⁴, ¹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ²HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁵Hospital La Fe, Valencia, Spain, ⁶Rheumatology department, Hospital La Fe, Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, Valencia, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politecnic La Fe, Valencia, Spain, ¹³Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁴Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: There is limited information about musculoskeletal involvement in Marfan syndrome (MS), especially concerning bone metabolism.Methods: We conducted a retrospective and descriptive study of patients…
Abstract Number: 2057 • ACR Convergence 2024
Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center
Hugo Madariaga.Ch¹, Valery Ascuña² and RV, Gamboa-Cardenas³, and Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas , Universidad Científica del Sur, ¹Clínica del Sur Sanna. Arequipa-Perú, Arequipa, Peru, ²Oftalmosalud Clinical Center. Arequipa-Perú, Arequipa, Peru, ³Universidad Científica del Sur, Lima, Lima, Peru
Background/Purpose: To determine clinical features of autoimmune uveitis (AU) and the associated factors with the reactivation subtype Methods: A transversal analysis from single center cohort (ophthalmologic/rheumatologic…
Abstract Number: 1099 • ACR Convergence 2023
Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Maria Salgado Guerrero¹ and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College…
Abstract Number: 1127 • ACR Convergence 2023
Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Maria Paula Alvarez Hernandez¹, Inés Pérez Sancristóbal¹, Alfredo Madrid García², Lara Borrego Sanz³, Cristina Hormigos martín¹, Beatriz García Tirado³, Mayte Ariño Gutiérrez³, Cristina lajas Petisco¹, Pedro Arriola Villalobos³, Esperanza Pato Cour³ and Luis Rodríguez Rodríguez¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIU) are characterized by inflammation of the middle layer of the eye wall and have a significant impact on patients' visual-related quality…
Abstract Number: 1130 • ACR Convergence 2023
Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI
Esperanza Pato¹, Lara Borrego-Sanz², Marta Domínguez³, Fernando Alonso⁴, Fayna Rodríguez-Gonazález⁵, Marta Tejera-Santana⁵, María del Mar Esteban-Ortega⁶, Isabel García-Lozano⁷, Lucia Martinez-Costa⁸, Samuel Gonzalez-Ocampo⁸, Maite Sainz de la Maza⁹, Aina Moll-Udina⁹, Zulema Plaza¹⁰, Alejandro Fonollosa-Calduch¹¹, Joseba Artaraz¹¹, Teresa Díaz-Valle¹², María Gurrea-Almela¹², David Diaz-Valle¹³ and Rosalía Méndez-Fernández¹³, ¹Hospital Clínico San Carlos, Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Ophthalmology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Hospital Doctor Negrín, Ophthalmology, Gran Canaria, Spain, ⁶Hospital Infanta Sofia, Madrid, Spain, ⁷Hospital Infanta Sofia, Ophthalmology, Madrid, Spain, ⁸Hospital Doctor Peset, Ophthalmology, Valencia, Spain, ⁹Hospital Clinic of Barcelona, Ophthalmology, Barcelona, Spain, ¹⁰Universidad Autónoma de Madrid, Madrid, Spain, ¹¹Hospital de Cruces, Ophthalmology, Bilbao, Spain, ¹²Hospital De Móstoles, Ophthalmology, Madrid, Spain, ¹³Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Standardized and validated outcome measures of disease activity are lacking in the treatment and assessment of uveitis, making it difficult to compare efficacy and…
Abstract Number: 1220 • ACR Convergence 2023
Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ)
Denise Kruzikas¹, Ann Eldred², Shelly Kafka³, Janet Church⁴, Katherine Hammitt⁴, Patricia Koochaki⁵ and Christina O'Donnell⁶, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Inc., Lake Bluff, IL, ³AbbVie, Inc., Norristown, PA, ⁴Sjögren’s Foundation, Reston, VA, ⁵ICON Clinical Research LLC, Raleigh, NC, ⁶ICON plc, Raleigh, NC
Background/Purpose: Dry eye is one of the most important and prevalent symptoms experienced by patients with Sjögren's Disease (SJD). The DED-SQ is a 12-item patient…
Abstract Number: 1554 • ACR Convergence 2023
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
Audrey Hermant¹, Yann Nguyen², Fleur Cohen³, Antoine Baudet⁴, Alban DEROUX⁵, Vincent Poindron⁶, Cécile-Audrey Durel⁷, Nicolas Girszyn⁸, Noémie Le Gouellec⁹, Benedicte Rouviere¹⁰, Helder Gil¹¹, Francois Maurier¹², Nicolas Noel¹³, Loic Raffray¹⁴, Hubert De Boysson¹⁵, Benoit Faucher¹⁶, Bertrand Godeau¹⁷, Pierre Lozach¹⁸, Claude Bachmeyer¹⁹, Alice Berezne⁴, Gilles Blaison²⁰, Brice Castel²¹, Guillaume Gondran²², Matthieu Groh²³, Stéphane Giorgiutti²⁴, Jeremy Keraen²⁵, Julie Magnant²⁶, Sebastien Monnier²⁷, Philippe Blanche²⁸, Dominique Monnet²⁹, Antoine Brezin²⁹ and Benjamin Terrier³⁰, ¹Hopital Cochin, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Sorbonne Université, Paris, France, ⁴CH Annecy, Annecy, France, ⁵CHU de Grenoble, Grenoble, France, ⁶Strasbourg, Strasbourg, France, ⁷CHU Lyon, Lyon, France, ⁸Rouen, Rouen, France, ⁹CH Valenciennes, Valenciennes, France, ¹⁰CHU Brest, Brest, France, ¹¹CHU Besancon, Besançon, France, ¹²CH Metz, Metz, France, ¹³CHU Bicetre, Le Kremlin-Bicêtre, France, ¹⁴CHU la Réunion, La Réunion, France, ¹⁵CHU Caen, Caen, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Henri Mondor, Créteil, France, ¹⁸CH Le Mans, Le Mans, France, ¹⁹CHU Tenon, Paris, France, ²⁰Hôpital Louis PASTEUR, Colmar, France, ²¹CH Tarbes, Tarbes, France, ²²CHU Limoges, Limoges, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CH Quimper, Quimper, France, ²⁶CHU Tours, Tours, France, ²⁷CH Versailles, Versailles, France, ²⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁹CHU Cochin, Paris, France, ³⁰Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The management of severe ocular involvement in Behçet's disease (BD) is an important issue with major functional implications due to the risk of blindness.…
Abstract Number: 1558 • ACR Convergence 2023
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Didar Ucar¹, Basak Ecem Bircan², Nigar Rustamli², Bilge Batu Oto¹, Vedat Hamuryudan³, Sinem Nihal Esatoglu³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
Abstract Number: 1559 • ACR Convergence 2023
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
Nuria Barroso-Garcia¹, Jose Luis Martin-Varillas², Lara Sanchez-Bilbao³, Ivan Ferraz Amaro⁴, Vanesa Calvo Río⁵, Alfredo Adán⁶, Inés Hernanz-Rodriguez⁷, Emma Beltran-Catalan⁸, David Diaz-Valle⁹, Marisa Hernandez-Garfella¹⁰, Lucia Martinez-Costa¹¹, Manuel Diaz-Llopis¹², Jose M Herreras¹³, Olga Maiz-Alonso¹⁴, Ignacio Torre-Salaberri¹⁵, Antonio Atanes Sandoval¹⁶, Santos Insua-Vilariño¹⁷, Raquel Almodovar¹⁸, Patricia Fanlo-Mateo¹⁹, Juan Ramon De Dios²⁰, Angel Garcia-Aparicio²¹, Sergio rodriguez-Montero²², Vega Jovani²³, Patricia Moya²⁴, Eva Peña Sainz-Pardo²⁵, Jose Luis Hernandez²⁶ and Ricardo Blanco²⁷, ¹Hospital Universitario Puerta del Mar, Cadiz, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Valdecilla Hospital, Santander, Spain, ⁶Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁸HOSPITAL DEL MAR, Barcelona, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, ¹¹Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹²Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, ¹³Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹⁴University Hospital Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ¹⁷Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, ¹⁸Alcorcón Foundation University Hospital, Madrid, Spain, ¹⁹Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁰Osakidetza, Vitoria, Spain, ²¹Hospital Universitario de Toledo, Toledo, Spain, ²²Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, ²³Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ²⁴Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ²⁵Pediatric, Hospital 12 de Octubre, Madrid, Spain, ²⁶Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
Abstract Number: 0136 • ACR Convergence 2023
The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use
Sophie Do, Jennifer Du, Jaejin An, Jim Wang and Antony Lin, Kaiser SCAL, Fontana, CA
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used for the treatment of various autoimmune diseases. The medication is generally well-tolerated. However, long-term use after 5 years may…
Abstract Number: 1915 • ACR Convergence 2023
Scleritis and Development of Autoimmune Disease: A Case Series
Tessalyn Morrison¹, Moriah Gottman², Marcia Friedman³ and Daniela Ghetie⁴, ¹University of Vermont, Burlington, VT, ²Oregon Health & Science University, Milwaukie, OR, ³Alpine Immune Sciences, Inc., Beaverton, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].